- Home
- VERI vs DSGN Comparison
VERI vs DSGN Comparison
Compare VERI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERI
- DSGN
- Stock Information
- Founded
- VERI 2014
- DSGN 2017
- Country
- VERI United States
- DSGN United States
- Employees
- VERI N/A
- DSGN N/A
- Industry
- VERI EDP Services
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- VERI Technology
- DSGN Health Care
- Exchange
- VERI Nasdaq
- DSGN Nasdaq
- Market Cap
- VERI 438.8M
- DSGN 418.1M
- IPO Year
- VERI 2017
- DSGN 2021
- Fundamental
- Price
- VERI $4.30
- DSGN $9.49
- Analyst Decision
- VERI Strong Buy
- DSGN Buy
- Analyst Count
- VERI 5
- DSGN 1
- Target Price
- VERI $10.00
- DSGN $13.00
- AVG Volume (30 Days)
- VERI 5.3M
- DSGN 443.2K
- Earning Date
- VERI 11-06-2025
- DSGN 11-05-2025
- Dividend Yield
- VERI N/A
- DSGN N/A
- EPS Growth
- VERI N/A
- DSGN N/A
- EPS
- VERI N/A
- DSGN N/A
- Revenue
- VERI $98,027,000.00
- DSGN N/A
- Revenue This Year
- VERI $19.12
- DSGN N/A
- Revenue Next Year
- VERI $18.83
- DSGN N/A
- P/E Ratio
- VERI N/A
- DSGN N/A
- Revenue Growth
- VERI 0.74
- DSGN N/A
- 52 Week Low
- VERI $1.22
- DSGN $2.60
- 52 Week High
- VERI $9.42
- DSGN $9.85
- Technical
- Relative Strength Index (RSI)
- VERI 41.48
- DSGN 72.66
- Support Level
- VERI $3.59
- DSGN $8.21
- Resistance Level
- VERI $4.50
- DSGN $8.80
- Average True Range (ATR)
- VERI 0.46
- DSGN 0.72
- MACD
- VERI -0.11
- DSGN 0.20
- Stochastic Oscillator
- VERI 30.72
- DSGN 84.86
About VERI Veritone Inc.
Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has a presence in the United States, the United Kingdom, France, Australia, Israel, and India.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.